Colon News and Research

RSS

Sigmoidoscopy comes up short for women in detection of polyps in the colon

A new multi-center study has reaffirmed the difference between the sexes – at least when it comes to colorectal cancer detection and prevention.

20 May 2005

Colon cancer missed in simple screening test

A new U.S. study has revealed that a commonly used screening tool for colon cancer, sigmoidoscopy, does not pick up precancerous growths in almost two-thirds of women and the failure rate is twice as high as in men.

18 May 2005

New blood tests for both prostate and colon cancer

Tessera Inc., a Seattle-based biomedical company is, in collaboration with Dr. Robert Getzenberg, Director of the Brady Urological Research Institute at Johns Hopkins University, developing blood tests for both prostate and colon cancer and expects to commence clinical trials on EPCA (Early Prostate Cancer Antigen), its first blood test for prostate cancer, before the end of this year.

18 May 2005

Regular exercise helps early stage colon cancer patients recover

Patients treated for early stage colon cancer fared significantly better if they exercised regularly at the level of an hour's walk six times a week, according to a study to be presented at the annual meeting of the American Society of Clinical Oncology.

17 May 2005

Drugs that block the enzyme Odc prevent the onset of cancers

The drug DFMO prevents cancer in laboratory models of lymphoma but fails to kill existing cancerous cells that have lost the ability to self-destruct, according to investigators at St. Jude Children's Research Hospital.

16 May 2005

Statin chemoprevention with minimal surveillance could prevent 96 percent of colon cancers

Ulcerative colitis affects about one out of every 2,000 Americans, and after living with the disease for 30 years, nearly 22 percent of those people will develop colon cancer.

16 May 2005

Remicade shows promise in treating ulcerative colitis

Results from two Phase III, placebo-controlled clinical trials found that approximately two-thirds of patients with moderate to severe, active ulcerative colitis (UC) treated with Remicade (infliximab, 5mg/kg) demonstrated a significant improvement in symptoms.

16 May 2005

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

16 May 2005

Colon cancer patients who took aspirin regularly fared better after surgery

Colon cancer patients who took aspirin regularly fared better after surgery, reducing their risk of disease recurrence and death by half compared to non-users, researchers will report at the annual meeting of the American Society of Clinical Oncology.

16 May 2005

Moderate recreational and work-related physical activity may reduce the risk of ovarian cancer

While the benefits of physical activity in reducing colon and breast cancer are well established, results of studies on exercise and ovarian cancer have been inconclusive. Because ovarian cancer has such a poor prognosis, it is even more important to identify modifiable lifestyle factors that could prevent it.

16 May 2005

Genetic biomarker that may improve quality of life during treatment for colorectal cancer

A Mayo Clinic-led study has revealed a genetic biomarker that can predict which patients are most likely to experience unwanted side effects from one of the most commonly used and highly effective chemotherapy regimens designed to treat colorectal cancer.

16 May 2005

Counting number of endothelial cells in blood may predict cancer treatment's effectiveness

Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy.

15 May 2005

Scientists inhibit tumor formation

By studying mice with skin cancer, researchers at the Huntsman Cancer Institute at the University of Utah discovered a way to inhibit a mutant gene found in up to 30 percent of human tumors.

9 May 2005

Bionomics files key U.S. patents relating to cancer drug target BNO69

Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.

9 May 2005

Researchers develop promising new gene network analysis method

Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.

8 May 2005

After surgery check colon tumors for signs of syndrome, study suggests

A new study suggests that, after surgery, all colon tumors should be tested to learn if the patient may have an inherited syndrome that carries an extremely high risk of cancer. It also suggests that this prescreening can be done using a relatively inexpensive microscopy test already used in hospital pathology laboratories.

5 May 2005

Critical lock and key mechanism found for the assembly of tumor blood vessels

A critical lock and key mechanism that allows the final step in the completion of new blood vessel formation has been identified by a University of California, San Diego (UCSD) School of Medicine team in research that promises to lead to a new way to halt tumor growth by cutting off the tumor blood supply.

3 May 2005

Gene variant that increases colon cancer risk

A paper published in this week's Journal of Clinical Oncology says Transforming Growth Factor Beta Receptor 1*6A (TGFBR1*6A) - a mutated gene present in nearly one in eight people and the most commonly inherited cancer susceptibility gene identified so far - might be responsible for a significant proportion of familial colorectal cancers.

2 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer, researchers at Vanderbilt University Medical Center reported this week.

1 May 2005